CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1 enrolled
Drug / intervention
Brontictuzumabdrug
Likely dose
Brontictuzumab 1.5 mg/Kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02662608
NCT02662608N/ACompleted
CompareCT.gov

NOTCH 1 Inhibitor Brontictuzumab for Adenoid Cystic Carcinoma Bearing Two Activating NOTCH1 Mutations

M.D. Anderson Cancer Center·interventional·Posted Jan 25, 2016·Updated Jun 14, 2017

In Brief

A clinical study evaluating Brontictuzumab for Adenoid Cystic Carcinoma. Completed, enrolled 1 participant across 1 site.

Detailed Summary

The goal of this study is to start treatment with the NOTCH1 inhibitor brontictuzumab in an attempt to control tumors and prolong survival. The therapy involves participant being given the drug brontictuzumab to treat adenoid cystic carcinoma (ACC) with NOTCH 1 mutations. This is considered an investigational treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenoid Cystic Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 25, 2016
Enrollment StartDec 29, 2015
Primary CompletionMar 6, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.4 years ago

Interventions

Brontictuzumabdrug

1.5 mg/Kg intravenously every three weeks.